Home » CMS Rejects HHS Call for Off-Label Avastin Endorsement
CMS Rejects HHS Call for Off-Label Avastin Endorsement
Medicare administrators are shooting down recommendations in a government study released Monday that adds fresh ammunition to claims off-label use of cancer drug Avastin for eye disease could save taxpayers billions of dollars.
Law360
Law360
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May